Related references
Note: Only part of the references are listed.Osimertinib as first-line treatment for advanced epidermal growth factor receptor mutation-positive non-small-cell lung cancer in a real-world setting (OSI-FACT)
Yoshihiko Sakata et al.
EUROPEAN JOURNAL OF CANCER (2021)
A nomogram for predicting brain metastases of EGFR-mutated lung adenocarcinoma patients and estimating the efficacy of therapeutic strategies
Jing Wang et al.
JOURNAL OF THORACIC DISEASE (2021)
Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study
Chiao-En Wu et al.
BMC CANCER (2021)
EGFR-Mutated Squamous Cell Lung Cancer and Its Association With Outcomes
Rui Jin et al.
FRONTIERS IN ONCOLOGY (2021)
A multicenter cohort study of osimertinib compared with afatinib as first-line treatment for EGFR-mutated non-small-cell lung cancer from practical dataset: CJLSG1903
K. Ito et al.
ESMO OPEN (2021)
Gefitinib Alone Versus Gefitinib Plus Chemotherapy for Non-Small-Cell Lung Cancer With Mutated Epidermal Growth Factor Receptor: NEJ009 Study
Yukio Hosomi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Overall Survival with Osimertinib in Untreated, EGFR-Mutated Advanced NSCLC
S. S. Ramalingam et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Afatinib for the Treatment of NSCLC Harboring Uncommon EGFR Mutations: A Database of 693 Cases
James Chih-Hsin Yang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal
Valerio Gristina et al.
CANCER TREATMENT REVIEWS (2020)
Concomitant TP53 Mutation Confers Worse Prognosis in EGFR-Mutated Non-Small Cell Lung Cancer Patients Treated with TKIs
Matteo Canale et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Predictors of Acquired T790M Mutation in Patients Failing First- or Second-Generation Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors
Chee-Shee Chai et al.
CANCER MANAGEMENT AND RESEARCH (2020)
An Observational Study of AcquiredEGFRT790M-Dependent Resistance to EGFR-TKI Treatment in Lung Adenocarcinoma Patients in Taiwan
Shang-Gin Wu et al.
FRONTIERS IN ONCOLOGY (2020)
CT Radiomics in Predicting EGFR Mutation in Non-small Cell Lung Cancer: A Single Institutional Study
Shanshan Wu et al.
FRONTIERS IN ONCOLOGY (2020)
Value of 18F-FDG PET/CT-Based Radiomics Nomogram to Predict Survival Outcomes and Guide Personalized Targeted Therapy in Lung Adenocarcinoma With EGFR Mutations
Bin Yang et al.
FRONTIERS IN ONCOLOGY (2020)
Efficacy and Safety of Afatinib for EGFR-mutant Non-small Cell Lung Cancer, Compared with Gefitinib or Erlotinib
Youjin Kim et al.
CANCER RESEARCH AND TREATMENT (2019)
Peritoneal carcinomatosis in non-small-cell lung cancer: retrospective multicentric analysis and literature review
Maria Ida Abbate et al.
FUTURE ONCOLOGY (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Intrinsic Resistance to EGFR-Tyrosine Kinase Inhibitors in EGFR-Mutant Non-Small Cell Lung Cancer: Differences and Similarities with Acquired Resistance
Eric Santoni-Rugiu et al.
CANCERS (2019)
Non-small cell lung cancer harbouring non-resistant uncommon EGFR mutations: Mutation patterns, effectiveness of epidermal growth factor receptor-tyrosine kinase inhibitors and prognostic factors
Lih-Chyun Chang et al.
EUROPEAN JOURNAL OF CANCER (2019)
Clinical outcomes and secondary epidermal growth factor receptor (EGFR) T790M mutation among first-line gefitinib, erlotinib and afatinib-treated non-small cell lung cancer patients with activating EGFR mutations
Yen-Ting Lin et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial
Kazuhiko Nakagawa et al.
LANCET ONCOLOGY (2019)
Molecular heterogeneity in lung cancer: from mechanisms of origin to clinical implications
Federica Zito Marino et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2019)
Clinical Factors Predicting Detection of T790M Mutation in Rebiopsy for EGFR-Mutant Non-small-cell Lung Cancer
Takahisa Kawamura et al.
CLINICAL LUNG CANCER (2018)
Osimertinib improves progression-free survival in NSCLC
Robert Stirrups
LANCET ONCOLOGY (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Comparison of the effects of the three major tyrosine kinase inhibitors as first-line therapy for non-small-cell lung cancer harboring epidermal growth factor receptor mutations
Chih-Yen Tu et al.
Oncotarget (2018)
The Association of Acquired T790M Mutation with Clinical Characteristics after Resistance to First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Lung Adenocarcinoma
Yen-Hsiang Huang et al.
CANCER RESEARCH AND TREATMENT (2018)
The alteration of T790M between 19 del and L858R in NSCLC in the course of EGFR-TKIs therapy: a literature-based pooled analysis
Hengrui Liang et al.
JOURNAL OF THORACIC DISEASE (2018)
1455PComparative analysis of overall survival using propensity score between first- and second-generation EGFR-TKI: Real world data of 1354 patients with EGFR mutant NSCLC
K Ito et al.
ANNALS OF ONCOLOGY (2018)
Preventing and treating brain metastases with three first-line EGFR-tyrosine kinase inhibitors in patients with EGFR mutation-positive advanced non-small cell lung cancer
Po-Lan Su et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label, phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2017)
Chang Gung Research Database: A multi-institutional database consisting of original medical records
Ming-Shao Tsai et al.
BIOMEDICAL JOURNAL (2017)
The impact of de novo liver metastasis on clinical outcome in patients with advanced non-small-cell lung cancer
Yu-Ping Chang et al.
PLOS ONE (2017)
Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
Keunchil Park et al.
LANCET ONCOLOGY (2016)
Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis
Eduardo Castanon et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
Yi-Long Wu et al.
LANCET ONCOLOGY (2014)
Nomogram Predicting Clinical Outcomes in Non-small Cell Lung Cancer Patients Treated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
Bhumsuk Keam et al.
CANCER RESEARCH AND TREATMENT (2014)
Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With EGFR Mutations
Lecia V. Sequist et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
EGFR Mutation Heterogeneity and the Mixed Response to EGFR Tyrosine Kinase Inhibitors of Lung Adenocarcinomas
Zhi-Yong Chen et al.
ONCOLOGIST (2012)
De Novo Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in EGFR Mutation-Positive Patients with Non-small Cell Lung Cancer
Masayuki Takeda et al.
JOURNAL OF THORACIC ONCOLOGY (2010)
Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
Tetsuya Mitsudomi et al.
LANCET ONCOLOGY (2010)
Gefitinib or Chemotherapy for Non-Small-Cell Lung Cancer with Mutated EGFR.
Makoto Maemondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Peritoneal carcinomatosis in lung cancer
Hsuan-Tsung Su et al.
RESPIROLOGY (2008)
Unbiased recursive partitioning: A conditional inference framework
Torsten Hothorn et al.
JOURNAL OF COMPUTATIONAL AND GRAPHICAL STATISTICS (2006)
Share Paper
